Brenipatide for Moderate-to-Severe COPD
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- Age
- 40 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 606 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
This trial is looking for adults with moderate-to-severe COPD to test a new treatment called Brenipatide. Participants will receive either the treatment or a placebo and will be monitored for about one year.
You may be able to join if
- I have been diagnosed with COPD for at least 12 months.
- I am a current or former smoker with a smoking history of at least 10 pack-years.
- I have moderate-to-severe COPD.
- I have a mMRC Dyspnea Scale grade of 2 or higher.
- I have had 2 or more moderate or 1 severe COPD flare-ups in the past year.
- I have been on stable COPD treatment for at least one month before the trial.
You may not be able to join if
- I have a known serious lung condition other than COPD.
- I have had a recent active infection before the trial.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when compared with placebo. The study will last approximately one year.
Loading trial locations…
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
CONTACT
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
CONTACT